EP1370240A1 - Neuroprotectants formulations and methods - Google Patents
Neuroprotectants formulations and methodsInfo
- Publication number
- EP1370240A1 EP1370240A1 EP02733809A EP02733809A EP1370240A1 EP 1370240 A1 EP1370240 A1 EP 1370240A1 EP 02733809 A EP02733809 A EP 02733809A EP 02733809 A EP02733809 A EP 02733809A EP 1370240 A1 EP1370240 A1 EP 1370240A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cerebrospinal
- flow
- fluid
- pathway
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims description 19
- 238000009472 formulation Methods 0.000 title description 12
- 239000004090 neuroprotective agent Substances 0.000 title description 9
- 239000012530 fluid Substances 0.000 claims abstract description 58
- 230000010412 perfusion Effects 0.000 claims abstract description 50
- 230000037361 pathway Effects 0.000 claims abstract description 43
- 230000006378 damage Effects 0.000 claims abstract description 31
- 241001465754 Metazoa Species 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 208000014674 injury Diseases 0.000 claims description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 230000008733 trauma Effects 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 230000000324 neuroprotective effect Effects 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 108010088751 Albumins Proteins 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 5
- SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- CKAKVKWRMCAYJD-UHFFFAOYSA-N 1-(3-ethylphenyl)-1-methyl-2-naphthalen-1-ylguanidine;hydrochloride Chemical compound Cl.CCC1=CC=CC(N(C)C(N)=NC=2C3=CC=CC=C3C=CC=2)=C1 CKAKVKWRMCAYJD-UHFFFAOYSA-N 0.000 claims description 3
- LPMRCCNDNGONCD-RITPCOANSA-N Selfotel Chemical compound OC(=O)[C@@H]1C[C@H](CP(O)(O)=O)CCN1 LPMRCCNDNGONCD-RITPCOANSA-N 0.000 claims description 3
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 claims description 3
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 claims description 2
- YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 claims description 2
- PXINDYJACXPZIN-UHFFFAOYSA-N 3-(4-chlorophenyl)-4-ethyl-1h-1,2,4-triazol-5-one Chemical compound N1C(=O)N(CC)C(C=2C=CC(Cl)=CC=2)=N1 PXINDYJACXPZIN-UHFFFAOYSA-N 0.000 claims description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 2
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 claims description 2
- 229930003347 Atropine Natural products 0.000 claims description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 2
- 229960000396 atropine Drugs 0.000 claims description 2
- 229950004794 dizocilpine Drugs 0.000 claims description 2
- 229950005455 eliprodil Drugs 0.000 claims description 2
- 229960003998 ifenprodil Drugs 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 2
- 229960004640 memantine Drugs 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229960001783 nicardipine Drugs 0.000 claims description 2
- 229960000715 nimodipine Drugs 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229960003370 pralidoxime Drugs 0.000 claims description 2
- JBKPUQTUERUYQE-UHFFFAOYSA-O pralidoxime Chemical compound C[N+]1=CC=CC=C1\C=N\O JBKPUQTUERUYQE-UHFFFAOYSA-O 0.000 claims description 2
- 229950000659 remacemide Drugs 0.000 claims description 2
- 229950009825 selfotel Drugs 0.000 claims description 2
- 230000003637 steroidlike Effects 0.000 claims description 2
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 claims description 2
- 229960002811 ziconotide Drugs 0.000 claims description 2
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- TZVQRMYLYQNBOA-KEKNWZKVSA-N benzyl n-[(2s)-4-methyl-1-[[1-(3-morpholin-4-ylpropylamino)-1,2-dioxopentan-3-yl]amino]-1-oxopentan-2-yl]carbamate Chemical compound N([C@@H](CC(C)C)C(=O)NC(CC)C(=O)C(=O)NCCCN1CCOCC1)C(=O)OCC1=CC=CC=C1 TZVQRMYLYQNBOA-KEKNWZKVSA-N 0.000 claims 2
- OBHWTRBRRFQGRJ-UHFFFAOYSA-N 2-(7-imidazol-1-yl-6-nitro-2,3-dioxo-4h-quinoxalin-1-yl)acetic acid;hydrate Chemical compound O.[O-][N+](=O)C=1C=C2NC(=O)C(=O)N(CC(=O)O)C2=CC=1N1C=CN=C1 OBHWTRBRRFQGRJ-UHFFFAOYSA-N 0.000 claims 1
- CWEHWZPCDBRUNO-WLHGVMLRSA-N 3-(1-benzylpiperidin-4-yl)-1-(2,3,4,5-tetrahydro-1h-1-benzazepin-8-yl)propan-1-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C=1C=C2CCCCNC2=CC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 CWEHWZPCDBRUNO-WLHGVMLRSA-N 0.000 claims 1
- DNCAZYRLRMTVSF-UHFFFAOYSA-N 4-(1-amino-1-carboxyethyl)benzoic acid Chemical group OC(=O)C(N)(C)C1=CC=C(C(O)=O)C=C1 DNCAZYRLRMTVSF-UHFFFAOYSA-N 0.000 claims 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 claims 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960001284 citicoline Drugs 0.000 claims 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims 1
- 229960005215 dichloroacetic acid Drugs 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- OZFSWVOEXHGDES-INIZCTEOSA-N lubeluzole Chemical compound C([C@@H](O)CN1CCC(CC1)N(C)C=1SC2=CC=CC=C2N=1)OC1=CC=C(F)C(F)=C1 OZFSWVOEXHGDES-INIZCTEOSA-N 0.000 claims 1
- 229950009851 lubeluzole Drugs 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- XUHMGFKQBWZWPO-UHFFFAOYSA-N tazomeline Chemical compound CCCCCCSC1=NSN=C1C1=CCCN(C)C1 XUHMGFKQBWZWPO-UHFFFAOYSA-N 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 46
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 13
- 235000015097 nutrients Nutrition 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 11
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 10
- 208000016192 Demyelinating disease Diseases 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000000278 spinal cord Anatomy 0.000 description 8
- 210000002330 subarachnoid space Anatomy 0.000 description 8
- 206010012305 Demyelination Diseases 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000003633 blood substitute Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 4
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 239000012867 bioactive agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 239000002430 glycine receptor antagonist Substances 0.000 description 4
- 210000004884 grey matter Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009529 traumatic brain injury Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- FSOCDJTVKIHJDC-OWOJBTEDSA-N (E)-bis(perfluorobutyl)ethene Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)\C=C\C(F)(F)C(F)(F)C(F)(F)C(F)(F)F FSOCDJTVKIHJDC-OWOJBTEDSA-N 0.000 description 3
- -1 Amino Nicardipine Chemical compound 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 208000034693 Laceration Diseases 0.000 description 3
- 208000009829 Lewy Body Disease Diseases 0.000 description 3
- 201000002832 Lewy body dementia Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000003703 cisterna magna Anatomy 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002461 excitatory amino acid Effects 0.000 description 3
- 239000003257 excitatory amino acid Substances 0.000 description 3
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 2
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 2
- 208000018126 Adrenomyeloneuropathy Diseases 0.000 description 2
- 206010052346 Brain contusion Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 108010024212 E-Selectin Proteins 0.000 description 2
- 102100023471 E-selectin Human genes 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 2
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 210000004289 cerebral ventricle Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 231100000481 chemical toxicant Toxicity 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000009519 contusion Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940027278 hetastarch Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000003140 lateral ventricle Anatomy 0.000 description 2
- 210000004558 lewy body Anatomy 0.000 description 2
- 108010049645 liposome-encapsulated hemoglobin Proteins 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- VOROEQBFPPIACJ-SCSAIBSYSA-N (2r)-2-amino-5-phosphonopentanoic acid Chemical compound OC(=O)[C@H](N)CCCP(O)(O)=O VOROEQBFPPIACJ-SCSAIBSYSA-N 0.000 description 1
- FAAVTENFCLADRE-NTSWFWBYSA-N (2r,4s)-4-(2h-tetrazol-5-ylmethyl)piperidine-2-carboxylic acid Chemical compound C1CN[C@@H](C(=O)O)C[C@H]1CC1=NNN=N1 FAAVTENFCLADRE-NTSWFWBYSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- UOCUSOBVEHOMMB-UHFFFAOYSA-N 2h-1$l^{6},2,3-benzothiadiazine 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)NN=CC2=C1 UOCUSOBVEHOMMB-UHFFFAOYSA-N 0.000 description 1
- MGNMVYXIKDNAKK-UHFFFAOYSA-N 3,3-bis(3-fluorophenyl)-n-methylpropan-1-amine;hydron;chloride Chemical compound Cl.C=1C=CC(F)=CC=1C(CCNC)C1=CC=CC(F)=C1 MGNMVYXIKDNAKK-UHFFFAOYSA-N 0.000 description 1
- VZRNTCHTJRLTMU-UHFFFAOYSA-N 7-chloro-3-methyl-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C1=C(Cl)C=C2S(=O)(=O)NC(C)NC2=C1 VZRNTCHTJRLTMU-UHFFFAOYSA-N 0.000 description 1
- OFUDZKKOKPGXOH-UHFFFAOYSA-N 8-(4-aminophenyl)-5-methyl-N-propyl-5H-[1,3]dioxolo[4,5-g]phthalazine-6-carboxamide Chemical compound C12=CC=3OCOC=3C=C2C(C)N(C(=O)NCCC)N=C1C1=CC=C(N)C=C1 OFUDZKKOKPGXOH-UHFFFAOYSA-N 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 206010060964 Arterial haemorrhage Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000001054 Basilar Skull Fracture Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010053942 Cerebral haematoma Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015769 Extradural haematoma Diseases 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 description 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000012484 Spinal Cord Vascular disease Diseases 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- 206010048992 Spinal cord haemorrhage Diseases 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000031809 Subdural Acute Hematoma Diseases 0.000 description 1
- 208000037132 Subdural Chronic Hematoma Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000018254 acute transverse myelitis Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 1
- 210000000576 arachnoid Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 batimastat Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 108010079785 calpain inhibitors Proteins 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002779 cholinesterase reactivator Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004414 clomethiazole Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical group OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000002597 diffusion-weighted imaging Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000007396 fibrous gliosis Effects 0.000 description 1
- XQGIZQWEZVJRDD-UHFFFAOYSA-N fluoro(methyl)phosphinic acid Chemical compound CP(O)(F)=O XQGIZQWEZVJRDD-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000006589 gland dysfunction Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 210000002441 meningeal artery Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 102000006239 metabotropic receptors Human genes 0.000 description 1
- 108020004083 metabotropic receptors Proteins 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000003018 neuroregenerative effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000001706 oxygenating effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229950011087 perflunafene Drugs 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 210000002975 pon Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 208000026843 stiff neck Diseases 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0464—Cerebrospinal fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/0476—Oxygenated solutions
Definitions
- This invention relates to neuroprotectant formulations or compositions useful for treating neurologic diseases and conditions that cause death or damage to neurological tissue, such as Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke, traumatic brain injury (TBI), brain hemorrhage, spinal cord traumatic injury, ischemia caused by surgical intervention or central nervous system ischemic or chemical injury.
- the cerebrospinal fluid (CSF) pathway system which intimately bathes and permeates brain and spinal cord tissues, constitutes a circulatory system within the body. Although it has some similarities to systemic vascular and lymphatic circulation, its anatomical arrangement differs considerably. Indeed, this system has been named the "third circulation" system.
- cerebrospinal fluid system constitutes a vast, complex and intimate avenue for access to central nervous tissue.
- Disclosed herein are methods of treating critical diseases and conditions of neuronal tissue using a perfusion of that tissue, methods of washing out toxic metabolic by-products with appropriate fluids, methods of treating certain neurologic diseases and conditions, and methods of delivering certain classes of agents.
- the invention provides a method of treating in an animal that has suffered damage to cerebrospinal tissue or that has an indication creating a risk of damage to cerebrospinal tissue, the method comprising: a. injecting a physiologically acceptable cerebrospinal perfusion fluid into a first catheter into the cerebrospinal pathway, which cerebrospinal perfusion fluid has a neuroprotecting effective amount of a neuroprotectant; b. withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and c. maintaining the flow for a period of time adapted to perfuse an affected tissue.
- the invention additionally provides a method of treating in an animal that has suffered damage to cerebrospinal tissue or that has an indication creating a risk of damage to cerebrospinal tissue comprising: injecting a cerebrospinal perfusion fluid into a first catheter into the cerebrospinal pathway, which fluid has a neuroprotective effective amount of a neuroprotectant, wherein the cerebrospinal perfusion fluid further comprises one or both of: (i) an emulsion-forming effective amount of a lipid composition comprised of lipids found in biological membranes, or (ii) 0.05 - 2.0 g/dL albumin; withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and maintaining the flow for a period of time adapted to perfuse an affected tissue.
- the invention also provides a method of treating a neurodegenerative disease comprising: injecting physiologically acceptable cerebrospinal perfusion fluid into a first catheter into the cerebrospinal pathway, which fluid has a neuroprotective effective amount of a neuroprotectant; withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and maintaining flow for a period of time adapted to perfuse an affected tissue.
- the invention further provides a method of treating stroke or trauma to cerebrospinal tissue comprising: a. injecting a physiologically acceptable cerebrospinal perfusion fluid into a first catheter into the cerebrospinal pathway, which fluid has a neuroprotective effective amount of a neuroprotectant; b. withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and c. maintaining the flow for a period of time adapted to perfuse an affected tissue.
- the invention provides a method of treating in an animal that has suffered damage to cerebrospinal tissue or that has an indication creating a risk of damage to cerebrospinal tissue comprising: a. injecting a cerebrospinal perfusion fluid into a first catheter into the cerebrospinal pathway, which fluid has a neuroprotective effective amount of a neuroprotectant; b. withdrawing fluid at a second catheter into the cerebrospinal pathway to create a flow and flow pathway between the first and second catheters; and c. maintaining the flow for a period of time adapted to perfuse an affected tissue.
- FIG. 1 illustrates a perfusion pathway.
- the inventive method can also be used to remove neurotoxic by-products while optionally providing oxygen, glucose, electrolytes and essential amino acids into neural tissue. If used in a rapidly exchanging cerebrospinal fluid perfusion system, such as is described in WO 01/39819 (the perfusion systems described therein are incorporated by reference, see below), the inventive composition and methods can be used both to supply these nutrients and, at the same time, remove metabolic waste.
- Diseases and Conditions Neurological tissue is placed at risk of death or damage under a variety of conditions such as ischemia, hemorrhage, trauma, or exposure to toxic chemicals.
- methylphosphonothiotic acid and Sarin (methylphosphonofluoridic acid)
- the invention is used to prevent or ameliorate such damage or death.
- the invention can also be used to ameliorate damage due to more chronic neurodegenerative diseases or disorders such as Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis.
- Formulation of a neuroprotectant into an artificial cerebral spinal fluid and perfusion of the central nervous system offers significant advantage over current methods for treating these diseases and conditions.
- neuroprotectant therapy is delivered systemically either orally or intravenously in the hope that therapeutic amounts cross the blood-brain barrier and reach the effected CNS tissues.
- Systemic administration gives little control as to the amount of neuroprotectant that reaches the effected tissue, or the duration of contact of the tissue with an effective amount of the neuroprotectant.
- CNS perfusion of the neuroprotectant(s) allows control of both dose and duration of exposure of the agent.
- the neuroprotectants are selected from the general classes such as excitatory amino acid inhibitors (such as NAALADase inhibitors, gamma-aminobutyric acid (GAB A) agonists, adenosine receptor modulators, metabotropic receptor (mGluR) antagonists, calcium channel blockers, or glutamate receptor (NMD A, AMP A, or Kainate) antagonists), free radical inhibitors or scavengers (such as nitric oxide synthase (NOS) inhibitors, antioxidants, cholinesterase reactivators (such as pralidoxime), muscarinic or cholinergic receptor antagonists (such as atropine), inhibitors of lactic acid synthesis, cyclooxygenase inhibitors, or lipooxygenase inhibitors), antiinflammatory agents (including inhibitors of leulcocyte adhesion molecules (e.g., ICAM-1, E-selectin, ELAM-1, and VCAM-1)), matrix metalloproteinase inhibitors (
- agents that are neuroprotectants include:
- D-AP5 D(-)-amino-5-phosphonopentanoic acid
- NMDA antagonist ( ⁇ )-6-(l(2)H-tetrazol-5- 0.001-.1 yl)methyldecahydroisoquinoline-3- carboxylic acid (LY-233536, NMDA antagonist) cis-( ⁇ )-4-[(2H-tetrazol-5- yl)methyl]piperidine-2- 0.001-.1 carboxylic acid (LY-233053, NMDA antagonist) Memantine (NMDA antagonist) 0.01-1 Remacemide (NMDA antagonist) 0.01-1 Dexanabinol (NMDA antagonist) 0.01-1 Sinnabidiol (HU-211, NMDA antagonist) 0.01-1 [2,3-dioxo-7-(lH-imidazol-l-yl)6-nitro-l,2,3,4- tetrahydro- 1 -quinoxal-inyl] acetic acid monohydrate (YM872, AMPA antagonist, i.e., antagonist of AMPA subtype of glutamate receptors) 7-
- AMPA antagonist GV 150525 A (glycine antagonist) 1-amionocyclopropanecarboxylic acid (ACPC, 1-100 glycine antagonist), and its methyl
- ACPCM ethyl
- ACPCE ethyl
- the diseases, conditions, syndromes or disorders that can be treated with the invention include neurodegenerative diseases (characterized by progressive loss of neural tissue), neurodegenerative disorders (marked by a loss of nerve cells), and those indications discussed in the following paragraphs of this Section.
- Demyelination in later life is a feature of many neurologic disorders; it can result from damage to nerves or myelin due to local injury, ischemia, toxic agents, or metabolic disorders. Extensive myelin loss is usually followed by axonal degeneration and often by cell body degeneration, both of which may be irreversible. However, re-myelination occurs in many instances, and repair, regeneration, and complete recovery of neural function can be rapid.
- MS multiple sclerosis
- Central demyelination i.e., of the spinal cord, brain, or optic nerves
- ALS amyotrophic lateral sclerosis
- MS plaques of demyelination, with destruction of oligodendroglia and paravascular inflammation, are disseminated throughout the CNS, primarily in the white matter, with a predilection for the lateral and posterior columns (especially in the cervical and dorsal regions), the optic nerves, and paraventricular areas. Tracts in the midbrain, pons, and cerebellum are also affected as is gray matter in the cerebrum and spinal cord. Cell bodies and axons are usually preserved, especially in recent lesions. Later, axons may be destroyed, especially in the long tracts, and a fibrous gliosis makes the tracts appear sclerotic.
- Acute disseminated encephalomyelitis is characterized by paravascular CNS demyelination, which can occur spontaneously but usually follows a viral infection or viral vaccination.
- Adrenoleukodystrophy and adrenomyeloneuropathy are rare X- linked recessive metabolic disorders characterized by adrenal gland dysfunction and widespread demyelination of the nervous system. Adrenoleukodystrophy occurs in young boys; adrenomyeloneuropathy, in adolescents.
- Leber's hereditary optic atrophy and related mitochondrial disorders are characterized primarily by bilateral loss of central vision, usually affecting young men in their late teens or early twenties.
- HTLN- associated myelopathy a slowly progressive spinal cord disease associated with infection by the human T-cell lymphotrophic virus, is characterized by spastic weakness of both legs.
- Preferred agents for use in demyelination diseases include tumor necrosis factor inhibitors such as T ⁇ RF:Fc and Nerve Growth Factors.
- Cerebral contusions and lacerations are severe injuries. Depending on severity, they are often accompanied by severe surface wounds and by basilar skull fractures or depression fractures. Acute subdural hematomas (blood between the dura mater and arachnoid, usually from bleeding of the bridging veins) and intracerebral hematomas are common in severe head injury. Along with severe brain edema, they account for most fatalities. Chronic subdural hematomas may not produce symptoms until several weeks after trauma. Although early diagnosis (2 to 4 wk after trauma) may be suggested by delayed neurologic deterioration, later diagnosis can be overlooked because of the time lapse between trauma and the onset of symptoms and signs.
- Subdural hematomas are more common in alcoholics and patients > 50 yr, in whom the head injury may have been relatively trivial, even forgotten.
- Epidural hematomas blood between the skull and dm-a mater
- Preferred agents for treating cerebral contusions and lacerations include free radical inhibitors and pre- and post-synaptic excitatory amino acid inhibitors.
- Spinal compression particularly acute spinal compression, spinal abscess and hematoma can also be treated with the methods of the invention.
- Preferred agents for use in these kinds of trauma or spinal compression include steroidal and non-steroidal antiinflammatory agents.
- Acute transverse myelitis is a syndrome in which acute inflammation affects gray and white matter in one or more adjacent thoracic segments. Some cases follow nonspecific viral infection or vaccination, suggesting an immunologic cause; others are associated with vasculitis, use of amphetamines or IN heroin use, Lyme disease, syphilis, tuberculosis, or parasitic or fungal agents. Usually, symptoms include ascending weakness and numbness of the feet and legs and difficulty voiding develop over a few days; they may progress over several more days to become severe, usually with global sensorimotor paraplegia below the lesion, urinary retention, and loss of bowel control. Occasionally, posterior column functions are spared, at least initially. Local back pain, headache, and stiff neck may be present.
- Preferred agents include immunoglobulins such as IGG.
- Dementias associated with damage to cerebrospinal tissue include Alzheimer's disease. This dementia is a progressive, inexorable loss of cognitive function associated with an excessive number of senile plaques in the cerebral cortex and subcortical gray matter, which also contains ⁇ -amyloid and neurofibrillary tangles consisting of tau protein.
- Lewy body dementia may be the second most common dementia after Alzheimer's disease. Lewy bodies are hallmark lesions of degenerating neurons in Parkinson's disease and occur in dementia with or without features of Parkinson's disease. In Lewy body dementia, Lewy bodies may predominate markedly or be intermixed with classic pathologic changes of Alzheimer's disease.
- Symptoms, signs, and course of Lewy body dementia resemble those of Alzheimer's disease, except hallucinations (mainly visual) are more common and patients appear to have an extraordinarily sensitivity to antipsychotic-induced extrapyramidal adverse effects. Cerebrovascular disease can destroy enough brain tissue to impair function, leading to dementia.
- Vascular dementia which includes impairment due to single, strategically located infarcts or to multiple small infarcts from small or medium-sized vessel disease, is more common in men and generally begins after age 70. It occurs more often in persons who have hypertension and/or diabetes mellitus or who abuse tobacco.
- Preferred agents for use in such dementias include albumin and immunoglobulins such as IGG.
- the neuroprotectant is selected based on the indication that creates a risk of damage to cerebrospinal tissue. Identification or diagnosis of the indication is conducted by methods known in the art. Similarly, those of skill in the art can identify appropriate neuroprotectants for the indication.
- the cerebrospinal perfusion fluid is an oxygen- carrying nutrient emulsion according to the following:
- the pH of the emulsion, or vehicle is in the physiological range, such as about pH 7.3.
- the amino acids include tryptophan.
- the cerebrospinal perfusion fluid is preferably formulated such that it is physiologic and can directly contact tissues of the neuraxis for an extended period of time, from hours to days, without causing side effects. For best performance, it is believed that the artificial cerebrospinal fluid should be appropriately buffered and contains appropriate amounts of amino acids, electrolytes and other compounds helpful to healthy metabolism. Thus, in preferred methods, these components do not need to be supplied tlirough equilibration with other body fluids.
- cerebrospinal perfusion fluid is formulated with nutrients, it can be termed "artificial cerebrospinal fluid" or "ACSF.”
- the cerebrospinal perfusion fluid is simplified CSPF is simplified, such as according to the following:
- the poly-fluorinated, oxygen-carrying compound is omitted.
- the amino acid nutrient components can be omitted. Ions are maintained to the degree required to avoid damage to cerebrospinal tissue. Appropriate amounts of oncotic agents are preferred.
- the cerebrospinal perfusion fluid preferably contains albumin component in the amounts recited above.
- tissue and cells will not fare well if exposed to large volumes of non- physiologic ionic solutions. Accordingly, appropriate electrolyte compositions at the tissue level are important when it is considered that the circulatory method of the present invention could dilute electrolytes fiom the region, to the detriment of cell membrane function. Desirably, sodium, potassium, calcium, magnesium, and chloride ions are carefully balanced in the neuroprotectant formulations of the present invention to create, to the degree possible, normal extra-cellular compositions.
- the neuroprotectant formulations of the invention preferably exclude four amino acids, glutathione, cysteine, ornithine and glutamine, from the group of amino acids included in the formulation, and preferably include sodium bicarbonate in an amount sufficient to increase the buffering capacity of the nutrient solution, in order to more closely resemble the cerebrospinal fluid of the subject.
- Kits for conveniently and safely generating fluorocarbon nutrient emulsion or a corresponding vehicle lacking poly-fluorinated, oxygen-carrying compound are described for example in US Patent Application No. 09/619,414, filed July 19, 2000 (the specific formulations and kits described therein are incorporated by reference as outlined below).
- the lipid and albumin component help flush or perfuse from cerebrospinal tissue metabolic by-products and cellular debris that accentuates cell damage.
- these components help flush cytokines and TNF ⁇ , which are believed to lead to shock.
- the neuroprotectant formulation is circulated tlirough this cerebrospinal fluid route by injecting it into brain vesicles and withdrawing it from the cisterna magna or the spinal subarachnoid space to nourish and to treat central nervous tissues.
- the fluid can be injected into the subarachnoid space and withdrawn from another subarachnoid position.
- oxygenated neuroprotectant formulation can be circulated to tissues to be treated in amounts sufficient to provide adequate gas exchange.
- the cerebrospinal perfusion fluid (for example comprising a neuroprotectant(s) identified above) can be introduced into the subarachnoid spaces tlirough a catheter that transverses the skull or spinal column and the meninges.
- the delivery point can be the lateral ventricles, subarachnoid space around the brain, cisterna magna or anywhere along the spine.
- the cerebrospinal perfusion fluid can be withdrawn from the subarachnoid space from any of these locations using a similar catheter.
- the cerebrospinal perfusion fluid can be returned to the delivery system, reconditioned as necessary to add components that have been consumed or remove undesirable components that have accumulated, and then returned to the subarachnoid space in recirculating fashion. This process can be continued for days if necessary, thereby directly exposing the neuraxis to the agent over an extended period of time.
- the cerebrospinal perfusion fluid is preferably not recirculated.
- the withdrawn fluid for a first 3-5 CSF volumes is preferably not recirculated by injection at the first catheter.
- This method has several advantages over other routes of administration, such as oral or intravenous administration.
- This invention provides a method of circulating the neuroprotectant throughout the neuraxis, thus exposing nervous system tissue to the agent in a more uniformly and continuously controlled dose than would otherwise be possible. It also provides a method of maintaining the neuroprotectant within a narrow concentration range, avoiding the necessity of high bolus concentrations over time. According to this method, the nervous system tissue can be exposed to the agent for extended period time, such as days, if necessary. Further, this method minimizes the amount of drug necessary to achieve a therapeutic effect.
- a flow pathway from the entry catheter e.g., a ventricular catheter into a lateral ventricle of the brain
- an exit point at a different location in the cerebral spinal pathway (e.g., into the intrathecal space of the lumbar (such as L4-L5) region of the spine) without prematurely inserting an cerebrospinal perfusion fluid containing, for example, neuroprotectant, oxygen-carrying compound, other emulsified components, or the like.
- a ventricular catheter 1 is inserted into a lateral ventrical
- a flow pathway can be established to a lumbar outflow catheter 6.
- vehicle can be used to establish the existence of a flow pathway (such as that illustrated) from the inflow catheter to the outflow catheter.
- the vehicle is infused under gravity feed, with the pressure head designed to avoid excessive intracranial pressure.
- the vehicle can be substituted with the cerebrospinal perfusion fluid.
- Cerebrospinal perfusion fluid is preferably perfused tlirough the cerebrospinal pathway for a period of time or for a flush volume adapted to effectively reduce the concentration of toxic by-products, or other molecular or debris components resulting from neurological damage.
- the volume perfused can be for example about 15 CSF volumes, where a "CSF volume" is the average volume of CSF fluid found in animals of comparable age to the subject. Preferably, at least about 1, 2, 4, 8, 15 or 30 CSF volumes are used.
- a flow rate in the range of 300-3,600 mL/hr is expected, resulting in the exchange of about 2-22 CSF volumes/hr.
- the perfusion is preferably with 300 to 3,600 mL/hr.
- perfusion can be maintained for an amount of time or volume effective to diminish toxin concentration at least 10-fold.
- the initial "perfusate" against which the reduction is measured is the initial CSF, or that portion of the initial CSF having the highest concentration of toxin.
- the perfusion can be conducted, for example, for 6, 12, 24 or 48 or more hours. Preferably the perfusion is conducted for between 6 hours and 48 hours or between 12 hours and 24 hours. More preferably, the perfusion is conducted for at least about 24 hours. Preferably, the perfusion is conducted for no more than about 120 hours (and in one embodiment, no more than about 72 hours).
- the perfusion is an adjunct to a longer term therapy that primarily seeks to deliver the neuroprotectant, and does not seek to perfusion out the cerebrospinal tissue.
- the perfusion is conducted to reduce the quantity of neurotoxic by-products. Thereafter, the focus is typically on delivery of the neuroprotectant, rather than perfusing fluid and delivering neuroprotectant. It will be recognized that where the catheters are left in place, these can be used to deliver neuroprotectant by injecting for example 0.1, 0.2 5 0.4, 1 or 2 or 5 CSF volumes or less.
- the longer-term delivery will be by a less invasive method, such as intravenous, oral, or any other recognized method of delivery.
- the post-perfusion administrations are typically done at least daily for at least seven days. If additional perfusions are conducted in this embodiment, the number of perfusions is typically small, such as two or three in total (including the original perfusion).
- Preferred treatment subjects among animals are mammals, preferably humans.
- the preferred compounds for use as non-aqueous oxygen transfer components are fluorocarbons, such as perfluorocarbons, perfluorinated alkyl polyethers, fiuoroethers, fluoramines, etc.
- fluorocarbons such as perfluorocarbons, perfluorinated alkyl polyethers, fiuoroethers, fluoramines, etc.
- Wlwar compounds witlim these groups range in molecular weight from 250 to 7000, their selection for use as non-aqueous transport components are based upon the combination of features of the proper vapor pressure, molecular weight, viscosity, ability to form an emulsion, emulsion stability and tissue distribution.
- fluorocarbons possess appropriate properties but they are for the most part non-toxic.
- One chief advantage of the CSF circulation route is that most or all of the neuroprotectant formulation can be removed by washing at the time of treatment termination. In this way long term cellular retention of oxygenating liquids can be avoided.
- Poly-fluorinated, oxygen-carrying compounds are known in the art. The basic requirement is effectiveness in carrying physiologically useful amounts of oxygen. Factors involved in selecting preferred such compounds include oxygen capacity, tissue retention (preferably minimized), emulsion stability, toxicity, and the like. Such compounds are described, for example, in: Riess et al., "Design Synthesis and Evaluation of Fluorocarbons and Surfactants for In vivo Applications New Perfluoroalkylated Polyhydroxylated Surfactants", Biomat. Artif. Cells Artif.
- oxygen-carrying compounds are those of the formula
- F44E trar ⁇ -Bis-perfluorobutyl ethylene (m and n each equal 4), which is also known as F44E.
- F44E formulations have a 25% greater oxygen carrying capacity than that of a prior nutrient solution made with perfluorodecalin, Bell et al., Neurology 37: 133, 1987.
- Formulations comprising F44E are less viscous and relatively easier to perfuse. Also preferred are those of the formula
- cell-free hemoglobin and liposome encapsulated hemoglobin may also be used as artificial oxygen carriers.
- Hemoglobin is a 4 subunit protein that is the naturally occurring oxygen carrier in red blood cells. Cell- free hemoglobin rapidly dissociates in the bloodstream, so artificial hemoglobins are chemically modified to prevent breakdown. Artificial hemoglobin's can be the product of surface modification, cross linkage, or polymerization. The production and use of cell-free hemoglobin is detailed in U.S. Pat. Nos.
- Hemoglobin can also be prevented from degradation by being encapsulated within a protective barrier, as in the case with liposome encapsulated hemoglobin, the production and use of which is presented in U.S. Pat. Nos. 5,049,391 ; 4,133,874; 4,776,991; 4,425,334, and 4,532,130.
- administering in an oxygen-carrying nutrient emulsion is also useful.
- Conditions for which administration in an oxygen-carrying nutrient emulsion is particularly useful include those which are accompanied by vasospasm resulting in ischemia, such as subarachnoid hemorrhage.
- bioactive agent is a substance such as a chemical that can act on a cell, virus, tissue, organ or organism, including but not limited to insecticides or drugs (i.e., pharmaceuticals) to create a change in the functioning of the cell, virus, organ or organism.
- methods of identifying bioactive agents of the invention are applied to organic molecules having molecular weight of about 1500 or less.
- cerebrospinal tissue Cerebrospinal tissue includes all tissues bathed by cerebrospinal fluid.
- effective amount The meaning of "effective amount” will be recognized by clinicians but includes an amount effective to reduce, ameliorate or eliminate one or more symptoms of the disease sought to be treated or the condition sought to be avoided or treated, or to otherwise produce a clinically recognizable change in the pathology of the disease or condition.
- One measure in the present context is a decrease in infarct volume, which can be measured for example with diffusion-weighted magnetic resonance imaging. See, Warach et al., Annals of Neurology 48: 713-722, 2000. Other measures include testing for motor control, coordination, memory, muscle strength, cognition, tactile sensation, vision, hearing, speech, and other measures of the function of cerebrospinal tissue. Those of ordinary skill will recognize that the amount is adjusted for the more pharmacokinetics operative with the invention.
- Neuroprotectants include bioactive agents that prevent or ameliorate damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma, or other condition of the cerebrospinal tissue.
- Neuroprotectants include neuroregenerative agents that have the functional effect of neuroprotection. Some such agents must be administered before the event, but others may be effective for some time after. Such agents act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.
- nutrient-providing effective amount A nutrient-providing effective amount of a substance is an amount that can be expected, provided sufficient amounts of other nutrients, to increase metabolism or reproduction of mammalian cells compared with nutrient solutions lacking that substance.
- oncotic agent substances, generally macromolecules, that are of a size that is not readily able to leave the body cavity or other fluid containing ' body spaces (such as the cerebrospinal pathway, including the cerebral ventricles and subarachnoid spaces) into which they are inserted.
- oncotic agents are exemplified by blood plasma expanders which are known in general as macromolecules having a size sufficient to inhibit their escape from the blood plasma through the circulatory capillary bed into the interstitial spaces of the body.
- Serum albumin preferably human serum albumin, is one well known blood plasma protein that can be used as an oncotic agent.
- Polysaccharide blood plasma expanders are often glucan polymers. For example,
- Hetastarch (a product of American Home Products) is an artificial colloid derived from a waxy starch composed almost entirely of amylopectin with hydroxyethyl ether groups introduced into the alpha (1-4) linked glucose units.
- the colloid properties of a 6% solution (wt/wt) of hetastarch approximate those of human serum albumin.
- Other polysaccharide derivatives may be suitable as oncotic agents in the blood substitute according to the invention. Among such other polysaccharide derivatives are hydroxymethyl alpha (1-4) or (1-6) polymers and cyclodextrins. In general, it is preferred that the polysaccharide is one that is non-antigenic.
- High molecular weight agents such as Dextran 70 having a molecular weight of about 70,000 Daltons are generally less preferred because they increase viscosity of the colloidal solution and impair the achievement of high flow rates.
- the oncotic agent is in an amount effective to provide, in conjunction with other components of a fluorocarbon nutrient emulsion or a nutrient solution, an oncotic pressure of one to seven torr.
- respiration is the physical and chemical processes by which an organism supplies its cells and tissues with the oxygen needed for metabolism and, preferably, relieves them of the carbon dioxide formed in energy-producing reactions.
- respiration-supporting amount is an amount that would, in model experiments, provide a statistically significant reduction in morbidity following a focal ischemic event.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79888001A | 2001-03-02 | 2001-03-02 | |
US798880 | 2001-03-02 | ||
PCT/US2002/005885 WO2002078670A1 (en) | 2001-03-02 | 2002-02-28 | Neuroprotectants formulations and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1370240A1 true EP1370240A1 (en) | 2003-12-17 |
EP1370240A4 EP1370240A4 (en) | 2004-09-22 |
Family
ID=25174500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02733809A Withdrawn EP1370240A4 (en) | 2001-03-02 | 2002-02-28 | Neuroprotectants formulations and methods |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1370240A4 (en) |
WO (1) | WO2002078670A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1616869B1 (en) | 1999-01-25 | 2012-04-04 | National Jewish Health | Substituted porphyrins and their therapeutic use |
AU2002312194B8 (en) | 2001-06-01 | 2008-05-15 | Aeolus Sciences, Inc. | Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
JP4758641B2 (en) * | 2003-12-12 | 2011-08-31 | 千寿製薬株式会社 | α-Ketoamide derivative, process for producing the same, and use thereof |
DE602004023873D1 (en) | 2003-12-12 | 2009-12-10 | Senju Pharma Co | USE OF THIS |
US20050182060A1 (en) * | 2004-02-13 | 2005-08-18 | Kelly Michael G. | 2-Substituted and 4-substituted aryl nitrone compounds |
WO2005089741A2 (en) * | 2004-03-17 | 2005-09-29 | Sosei R&D Ltd. | The treatment of inflammatory disorders and pain using beta-aminoalcohols |
WO2006068199A1 (en) * | 2004-12-22 | 2006-06-29 | Mochida Pharmaceutical Co., Ltd. | Metabolically stable 3-oxy-1,2,4-triazole derivatives |
JP2006213611A (en) * | 2005-02-02 | 2006-08-17 | Suzuka Univ Of Medical Science | Preventive or therapeutic agent for stroke or sequela of stroke containing 1-aminocyclopropane carboxylic acid or the like as main ingredient |
PT1874311E (en) | 2005-04-15 | 2011-11-25 | Res & Innovation S P A | A method for preventing, delaying or reverting abnormal amyloid deposition |
ES2332846B1 (en) * | 2007-10-26 | 2010-07-08 | Grifols, S.A. | USE OF THERAPEUTIC HUMAN ALBUMIN FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS AFFECTED BY COGNITIVE DISORDERS. |
US20090118376A1 (en) * | 2007-11-02 | 2009-05-07 | Ru-Band Lu | Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia |
WO2009123569A1 (en) * | 2008-03-31 | 2009-10-08 | Agency For Science, Technology And Research | Method for treating neurological disorders with imidazolium and imidazolinium compounds |
CA2725012C (en) * | 2008-05-23 | 2019-05-07 | National Jewish Health | Methods for treating injury associated with exposure to an alkylating species |
EP2338492A1 (en) * | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686085A (en) * | 1980-04-14 | 1987-08-11 | Thomas Jefferson University | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
US4840617A (en) * | 1980-04-14 | 1989-06-20 | Thomas Jefferson University | Cerebral and lumbar perfusion catheterization apparatus for use in treating hypoxic/ischemic neurologic tissue |
US5085630A (en) * | 1980-04-14 | 1992-02-04 | Thomas Jefferson University | Oxygenated fluorocarbon nutrient solution |
WO2000050058A1 (en) * | 1999-02-26 | 2000-08-31 | Marcus Keep | Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5512544A (en) * | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
US5980480A (en) * | 1996-07-11 | 1999-11-09 | Cs Fluids, Inc. | Method and apparatus for treating adult-onset dementia of the alzheimer's type |
US5977174A (en) * | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
-
2002
- 2002-02-28 EP EP02733809A patent/EP1370240A4/en not_active Withdrawn
- 2002-02-28 WO PCT/US2002/005885 patent/WO2002078670A1/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686085A (en) * | 1980-04-14 | 1987-08-11 | Thomas Jefferson University | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
US4840617A (en) * | 1980-04-14 | 1989-06-20 | Thomas Jefferson University | Cerebral and lumbar perfusion catheterization apparatus for use in treating hypoxic/ischemic neurologic tissue |
US5085630A (en) * | 1980-04-14 | 1992-02-04 | Thomas Jefferson University | Oxygenated fluorocarbon nutrient solution |
WO2000050058A1 (en) * | 1999-02-26 | 2000-08-31 | Marcus Keep | Cerebrospinal and vascular pharmaceutical composition and process for preparing the same |
Non-Patent Citations (2)
Title |
---|
BHARDWAJ A. ET AL.: "Adenosine modulates N-Methyl-D-Aspartate-stimulated hippocampal nitric oxide production in vivo" STROKE, vol. 26, no. 9, September 1995 (1995-09), pages 1627-1633, XP009034612 * |
See also references of WO02078670A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002078670A1 (en) | 2002-10-10 |
EP1370240A4 (en) | 2004-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bachevalier et al. | Mnemonic and neuropathological effects of occluding the posterior cerebral artery in Macaca mulatta | |
RU2194527C2 (en) | Method for treating ischemia and cerebral lesion with a neuroprotector preparation | |
US6796966B2 (en) | Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal | |
EP1370240A1 (en) | Neuroprotectants formulations and methods | |
KR101932831B1 (en) | Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage | |
JP2020073595A (en) | Methods of intravenous administration of glyburide and other drugs | |
Williams et al. | Ascending myeloencephalopathy due to intrathecal vincristine sulfate. A fatal chemotherapeutic error | |
JPH1095730A (en) | Brain function improving agent | |
MX2008016133A (en) | S1p receptor modulators for treating multiple sclerosis. | |
US6500809B1 (en) | Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith | |
JPH09503778A (en) | Analgesics and their use | |
US20020193285A1 (en) | Neuroprotectants formulations and methods | |
JPH09503777A (en) | Levobupivacaine useful for the treatment of chronic pain | |
EA010948B1 (en) | Lactate containing pharmaceutical composition and uses thereof | |
US6689756B2 (en) | Treatment of neurological disease | |
EP2925857A1 (en) | Use of trpv4 antagonists to ameliorate hydrocephalus and related materials and methods | |
JP4890266B2 (en) | Medicament for recovery from anesthesia comprising D-ribose | |
Ross et al. | Effect of nimodipine or methylprednisolone on recovery from acute experimental spinal cord injury in rats | |
Zhou et al. | Perfluorocarbon emulsions improve cognitive recovery after lateral fluid percussion brain injury in rats | |
Merker et al. | Neurotoxicity of adriamycin (doxorubicin) perfused through the cerebrospinal fluid spaces of the rhesus monkey | |
NZ198435A (en) | Pharmaceutical compositions containing a salt of 1-(2,3,4-trimethoxybenzyl)piperazine | |
RU2294193C1 (en) | Method for protecting the brain against ischemia | |
ES2210025T3 (en) | PHARMACEUTICAL AGENT FOR THE TREATMENT OF CONVULSIVE STATES. | |
Smith et al. | Anaphylactoid reaction to chymopapain | |
RU2153891C2 (en) | Method of treating epilepsy in children |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030919 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040811 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61P 25/28 B Ipc: 7A 61K 47/08 B Ipc: 7A 61K 38/38 B Ipc: 7A 61K 9/107 A |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040901 |